<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04211740</url>
  </required_header>
  <id_info>
    <org_study_id>OCH-NCNP1-02</org_study_id>
    <nct_id>NCT04211740</nct_id>
  </id_info>
  <brief_title>Phase II Clinical Trial of OCH-NCNP1</brief_title>
  <official_title>Efficacy and Safety of OCH-NCNP1 in Patients With Relapsing Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Center of Neurology and Psychiatry, Japan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Center of Neurology and Psychiatry, Japan</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to assess the efficacy and safety of OCH-NCNP1 compared to placebo in
      subjects diagnosed with relapsing remitting multiple sclerosis (RRMS) and secondary
      progressive mltiple sclerosis (SPMS) .
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">December 6, 2019</start_date>
  <completion_date type="Anticipated">October 14, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The rate of the patients who identified new or enlarging T2 lesions on MRI scans compared to baseline</measure>
    <time_frame>Change from screening at Month 6.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>annual relapse rate</measure>
    <time_frame>Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detection of asymptomatic</measure>
    <time_frame>Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expanded Disability Status Scale (EDSS) / Functional Scale (FS)</measure>
    <time_frame>screening, 4weeks, 8 weeks, 12 weeks, 16weeks, 20 weeks, 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of sustained reduction in disability (SRD)</measure>
    <time_frame>Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of MRI</measure>
    <time_frame>Change from screening at Month 3 and 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of No evidence of disease activity (NEDA)</measure>
    <time_frame>Change from screening at Month 3 and 6</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Multiple Sclerosis, Relapsing-Remitting</condition>
  <condition>Multiple Sclerosis, Secondary Progressive</condition>
  <arm_group>
    <arm_group_label>OCH-NCNP1 3 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OCH-NCNP1</intervention_name>
    <description>OCH-NCNP1 3mg is supplied as granules and take orally once a week.</description>
    <arm_group_label>OCH-NCNP1 3 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo is supplied as granules and take orally once a week.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject with Multiple Sclerosis eligible for enrolment in the study must meet all of
             the following criteria:

               1. Provision of written informed consent to participate in this study

               2. Patients diagnosed as relapsing remitting multiple sclerosis based on modified
                  McDonald criteria in 2017

               3. Relape must have been confirmed by a neurologist at least twice within 24 months,
                  or once within 12 months before enrollment

               4. Have at least one T2 lesion on MRI scans at screening

               5. EDSS less than or equal to 7

               6. 20 =&lt; Age &lt; 65

               7. Promise to prevent conception for at least 90 days after the last administration

               8. Neurological stability has been confirmed by a neurologist

        Exclusion Criteria:

          -  Subject with MS patients meeting any of the following criteria must not be enrolled in
             the study:

               1. Diagnosed as Neuromyelitis Optica

               2. Women who are pregnant or lactating

               3. Patients who is prohibited MRI

               4. Patients who are allergic to Gd-contrast medium

               5. History of liver diseases or liver transplantation

               6. Liver dysfunction in the screening test and baseline physical examination

               7. History of cancer past five years

               8. Negative for herpes zoster virus antibody

               9. Positive for Syphilis serum reaction

              10. Positive for Beta-glucan or positive for T-spot

              11. Positive for Anti-Aquaporin 4 antibody

              12. History of HIV infection

              13. History of HBV or HCV infection

              14. History of Transplantation

              15. Use of any other investigational agents and/or experimental agents within 4
                  months prior to the first anticipated administration of study medication.

              16. History of blood donation (200 ml within 2 months, 400 ml within 3 months) prior
                  to the first anticipated administration of study medication

              17. Lymphocyte number &lt; 600 /mm3 in peripheral blood

              18. Current diagnosed or suspected infectious diseases

              19. Compromised Patients

              20. Inflammatory Bowel disease

              21. Subjects with prolongation of QT/QTc interval

              22. History or have risk of torsade de pointes

              23. Taking the medicine which has risk of prolongation of QT/QTc interval

              24. History of severe allergy of medicine or food

              25. History or current of drug/ alcohol addiction

              26. Bronchial Asthma

              27. Epilepsy Other protocol-defined exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tomoko Okamoto, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Center of Neurology and Psychiatry</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Center of Neurology and Psychiatry</name>
      <address>
        <city>Tokyo</city>
        <zip>187-8551</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 17, 2019</study_first_submitted>
  <study_first_submitted_qc>December 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 26, 2019</study_first_posted>
  <last_update_submitted>December 23, 2019</last_update_submitted>
  <last_update_submitted_qc>December 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Center of Neurology and Psychiatry, Japan</investigator_affiliation>
    <investigator_full_name>Tomoko Okamoto</investigator_full_name>
    <investigator_title>Medical director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
    <mesh_term>Multiple Sclerosis, Chronic Progressive</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

